The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The NF-κB pathways have been implicated in tumorigenesis in several lymphoid malignancies, including non-Hodgkin's and Hodgkin's lymphomas. However, the antiapoptotic functions and the mechanism responsible for signaling through each NF-κB pathway remain to be elucidated. In the current study, lymphoma cell lines with constitutively active NF-κB were found to be resistant to inducers of the extrinsic and intrinsic apoptosis pathways. Resistance to cell death resulted from blocks early and late in the apoptosis cascade. Several NF-κB target genes were overexpressed in these cell lines, including Bcl-xL, Fas-associated death domain-like IL-1β-converting enzyme inhibitor protein, cellular inhibitor of apoptosis, and X inhibitor of apoptosis. Inhibition of the canonical or noncanonical NF-κB pathways with small interfering RNAs or adenovirus expressing a stable form of inhibitor of NF-κB (IκB) enhanced sensitivity to apoptosis inducers and resulted in lower levels of Bcl-xL or Fas-associated death domain-like IL-1β-converting enzyme inhibitor protein, cellular inhibitor of apoptosis, and X inhibitor of apoptosis. These findings demonstrate an important role of both NF-κB pathways in mediating resistance to apoptosis and distinctive antiapoptotic downstream target gene profiles responsible for this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB, an Evolutionarily Conserved Mediator of Immune and Inflammatory Responses
Xiao, C., & Ghosh, S. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-387-24180-9_5 · Cited by 167
Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-κB pathway
Kfoury, Y., Nasr, R., Hermine, O., de Thé, H., & Bazarbachi, A. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401624 · Cited by 40
Cited by
NF-κB and cancer — identifying targets and mechanisms
Naugler, W. E., & Karin, M. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.020 · Cited by 636
Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Jost, P. J., & Ruland, J. (2007) · Blood · doi:10.1182/blood-2006-07-025809 · Cited by 408
Oh, J., Weng, S., Felton, S. K., Bhandare, S., Riek, A., Butler, B., Proctor, B. M., Petty, M., Chen, Z., Schechtman, K. B., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.856070 · Cited by 387
Self-citationNuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
A Time to Kill: Targeting Apoptosis in Cancer
Koff, J., Ramachandiran, S., & Bernal-Mizrachi, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022942 · Cited by 279
Self-citation
Metadata
- Authors
- Bernal-Mizrachi, L., Lovly, C. M., & Ratner, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-06-13
- Volume
- 103
- Issue
- 24
- Pages
- 9220-9225
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2005798625
- Cited by
- 120
- References
- 2
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas. https://app.cochat.ai/papers/10.1073/pnas.0507809103
- The paper
- Bernal-Mizrachi, L., Lovly, C. M., & Ratner, L. (2006). The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0507809103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.